Five months after selling a cancer drug to Lilly for up to $2.5 billion, Scorpion has debuted a successor company led by its ...

The spinout, dubbed Antares Therapeutics, will be fueled by a $177 million series A round co-led by Omega Funds, Atlas ...

Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

Going to college has consistently conferred a large wage premium. We show that the relative premium received by lower-income Americans has halved since 1960. We decompose this steady rise in ...

Cullinan Therapeutics (NASDAQ:CGEM) signed a deal with Genrix Bio for an exclusive license for velinotamig, a bispecific T ...

PYC Therapeutics (ASX: PYC) presented its Q2 2025 investor webinar on May 30, outlining progress across its genetic medicine pipeline while facing continued market skepticism.

Beam Therapeutics' pipeline progress remains slow, with BEAM-101 still recruiting and CAR-T programs discontinued to reduce cash burn. Gene therapy markets targeted by Beam, such as SCD and AATD ...

Over 200 patients were dosed, and 365 enrolled in the Nex-Z MAGNITUDE trial, aiming for 765 by early 2027. Intellia plans BLA filing for NTLA-2002 in HAE by late 2026, with a U.S. launch targeted ...

Fate Therapeutics, Inc. (NASDAQ:FATE) announced today that it will present groundbreaking clinical data from its Phase 1 trial of FT819, an off-the-shelf, iPSC-derived CAR T-cell therapy ...

A federal judge had dismissed a challenge from the Standing Rock Sioux seeking to shutter the pipeline, saying their suit was premature. The Standing Rock Sioux Tribe is launching the latest round ...